Addition of HER2 and CD44 to 18F-FDG PET-based clinico-radiomic models enhances prediction of neoadjuvant chemoradiotherapy response in esophageal cancer.
Roelof J BeukingaDa WangArend KarrenbeldWillemieke P M DijksterhuisHette FaberJohannes G M BurgerhofVéronique E M MulRiemer H J A SlartRobert P CoppesJohn Th M PlukkerPublished in: European radiology (2020)
• A multimodality approach, integrating independent genomic and radiomic information, is promising to improve prediction of γpCR in patients with esophageal cancer. • HER2 and CD44 are potential biological tumor markers in the initial work-up of patients with esophageal cancer. • Prediction models combining 18F-FDG PET radiomic features with HER2 and CD44 may be useful in the decision to omit surgery after neoadjuvant chemoradiotherapy in patients with esophageal cancer.